Nanomedicine in cancer immunotherapy:
Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel,...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
London ; San Diego, CA ; Cambridge, MA
Academic Press, an imprint of Elsevier
[2024]
|
| Schlagworte: | |
| Zusammenfassung: | Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments |
| Beschreibung: | 1. Immunoadjuvants for cancer immunotherapy; 2. Nanotechnology as an emerging option in cancer immunotherapy; 3. Different administration routes for nanovectors in cancer immunotherapy; 4. Two-dimensional materialbased nanomedicines for cancer immunotherapy; 5. Hydrogel-based nanomedicines for cancer immunotherapy; 6. Exosomes-based nanomedicines for cancer immunotherapy; 7. Lipid-based nanomedicines for cancer immunotherapy; 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy; 9. Liposome-based nanomedicines for cancer immunotherapy; 10. Biomembrane-based nanoparticles for cancer immunotherapy; 11. Dendrimer-based nanomedicines for cancer immunotherapy; 12. Magnetic nanocarriers for cancer immunotherapy; 13. Inhaled delivery of immunotherapy for treatment of lung cancer; 14. Nano-based vaccination and their administration routes in cancer immunotherapy; 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy |
| Beschreibung: | xxiii, 544 Seiten Illustrationen |
| ISBN: | 9780443187704 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049518260 | ||
| 003 | DE-604 | ||
| 005 | 20240220 | ||
| 007 | t | ||
| 008 | 240125s2024 a||| |||| 00||| eng d | ||
| 020 | |a 9780443187704 |c paperback |9 978-0-443-18770-4 | ||
| 035 | |a (OCoLC)1424569508 | ||
| 035 | |a (DE-599)BVBBV049518260 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 245 | 1 | 0 | |a Nanomedicine in cancer immunotherapy |c edited by Prashant Kesharwani |
| 264 | 1 | |a London ; San Diego, CA ; Cambridge, MA |b Academic Press, an imprint of Elsevier |c [2024] | |
| 264 | 4 | |c © 2024 | |
| 300 | |a xxiii, 544 Seiten |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a 1. Immunoadjuvants for cancer immunotherapy; 2. Nanotechnology as an emerging option in cancer immunotherapy; 3. Different administration routes for nanovectors in cancer immunotherapy; 4. Two-dimensional materialbased nanomedicines for cancer immunotherapy; 5. Hydrogel-based nanomedicines for cancer immunotherapy; 6. Exosomes-based nanomedicines for cancer immunotherapy; 7. Lipid-based nanomedicines for cancer immunotherapy; 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy; 9. Liposome-based nanomedicines for cancer immunotherapy; 10. Biomembrane-based nanoparticles for cancer immunotherapy; 11. Dendrimer-based nanomedicines for cancer immunotherapy; 12. Magnetic nanocarriers for cancer immunotherapy; 13. Inhaled delivery of immunotherapy for treatment of lung cancer; 14. Nano-based vaccination and their administration routes in cancer immunotherapy; 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy | ||
| 520 | |a Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments | ||
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 700 | 1 | |a Kesharwani, Prashant |0 (DE-588)1233370847 |4 edt | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034864155 | ||
Datensatz im Suchindex
| _version_ | 1804186338158706688 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Kesharwani, Prashant |
| author2_role | edt |
| author2_variant | p k pk |
| author_GND | (DE-588)1233370847 |
| author_facet | Kesharwani, Prashant |
| building | Verbundindex |
| bvnumber | BV049518260 |
| ctrlnum | (OCoLC)1424569508 (DE-599)BVBBV049518260 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02848nam a2200301 c 4500</leader><controlfield tag="001">BV049518260</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240220 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">240125s2024 a||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780443187704</subfield><subfield code="c">paperback</subfield><subfield code="9">978-0-443-18770-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1424569508</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049518260</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Nanomedicine in cancer immunotherapy</subfield><subfield code="c">edited by Prashant Kesharwani</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London ; San Diego, CA ; Cambridge, MA</subfield><subfield code="b">Academic Press, an imprint of Elsevier</subfield><subfield code="c">[2024]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2024</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxiii, 544 Seiten</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">1. Immunoadjuvants for cancer immunotherapy; 2. Nanotechnology as an emerging option in cancer immunotherapy; 3. Different administration routes for nanovectors in cancer immunotherapy; 4. Two-dimensional materialbased nanomedicines for cancer immunotherapy; 5. Hydrogel-based nanomedicines for cancer immunotherapy; 6. Exosomes-based nanomedicines for cancer immunotherapy; 7. Lipid-based nanomedicines for cancer immunotherapy; 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy; 9. Liposome-based nanomedicines for cancer immunotherapy; 10. Biomembrane-based nanoparticles for cancer immunotherapy; 11. Dendrimer-based nanomedicines for cancer immunotherapy; 12. Magnetic nanocarriers for cancer immunotherapy; 13. Inhaled delivery of immunotherapy for treatment of lung cancer; 14. Nano-based vaccination and their administration routes in cancer immunotherapy; 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kesharwani, Prashant</subfield><subfield code="0">(DE-588)1233370847</subfield><subfield code="4">edt</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034864155</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV049518260 |
| illustrated | Illustrated |
| index_date | 2024-07-03T23:24:25Z |
| indexdate | 2024-07-10T10:09:32Z |
| institution | BVB |
| isbn | 9780443187704 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034864155 |
| oclc_num | 1424569508 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | xxiii, 544 Seiten Illustrationen |
| publishDate | 2024 |
| publishDateSearch | 2024 |
| publishDateSort | 2024 |
| publisher | Academic Press, an imprint of Elsevier |
| record_format | marc |
| spelling | Nanomedicine in cancer immunotherapy edited by Prashant Kesharwani London ; San Diego, CA ; Cambridge, MA Academic Press, an imprint of Elsevier [2024] © 2024 xxiii, 544 Seiten Illustrationen txt rdacontent n rdamedia nc rdacarrier 1. Immunoadjuvants for cancer immunotherapy; 2. Nanotechnology as an emerging option in cancer immunotherapy; 3. Different administration routes for nanovectors in cancer immunotherapy; 4. Two-dimensional materialbased nanomedicines for cancer immunotherapy; 5. Hydrogel-based nanomedicines for cancer immunotherapy; 6. Exosomes-based nanomedicines for cancer immunotherapy; 7. Lipid-based nanomedicines for cancer immunotherapy; 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy; 9. Liposome-based nanomedicines for cancer immunotherapy; 10. Biomembrane-based nanoparticles for cancer immunotherapy; 11. Dendrimer-based nanomedicines for cancer immunotherapy; 12. Magnetic nanocarriers for cancer immunotherapy; 13. Inhaled delivery of immunotherapy for treatment of lung cancer; 14. Nano-based vaccination and their administration routes in cancer immunotherapy; 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments (DE-588)4143413-4 Aufsatzsammlung gnd-content Kesharwani, Prashant (DE-588)1233370847 edt |
| spellingShingle | Nanomedicine in cancer immunotherapy |
| subject_GND | (DE-588)4143413-4 |
| title | Nanomedicine in cancer immunotherapy |
| title_auth | Nanomedicine in cancer immunotherapy |
| title_exact_search | Nanomedicine in cancer immunotherapy |
| title_exact_search_txtP | Nanomedicine in cancer immunotherapy |
| title_full | Nanomedicine in cancer immunotherapy edited by Prashant Kesharwani |
| title_fullStr | Nanomedicine in cancer immunotherapy edited by Prashant Kesharwani |
| title_full_unstemmed | Nanomedicine in cancer immunotherapy edited by Prashant Kesharwani |
| title_short | Nanomedicine in cancer immunotherapy |
| title_sort | nanomedicine in cancer immunotherapy |
| topic_facet | Aufsatzsammlung |
| work_keys_str_mv | AT kesharwaniprashant nanomedicineincancerimmunotherapy |